Continuously variable (or graded) biomarkers are generally less helpful in guiding therapy choices than dichotomous biomarkers (present vs absent), unless there is a marked nonlinear relationship between biomarker expression and drug benefit (as with estrogen receptors in breast cancer). This evidence concerns the gene ESR1 and breast carcinoma.